Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Medical Center, New York, New York.
Division of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington.
Inflamm Bowel Dis. 2019 Jan 1;25(1):27-32. doi: 10.1093/ibd/izy205.
The Crohn's & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure.10.1093/ibd/izy205_video1izy205.video15799266615001.
克罗恩病和结肠炎基金会通过 RISK 和 PROTECT 研究,促进了儿科炎症性肠病(IBD)的变革性研究,为全面了解疾病的分子机制和儿童治疗反应的预测因素奠定了基础。尽管取得了这些进展,但儿童仍然缺乏及时了解 IBD 最新治疗进展的途径。克罗恩病和结肠炎基金会于 2018 年 1 月在首届克罗恩病和结肠炎大会上召集了一个儿童炎症性肠道疾病(PRO-KIIDS)临床创新会议,以制定如何推进 IBD 儿童的护理。工作组选择了 2 个优先事项:(1)加快向 IBD 儿童提供治疗方法,(2)在促进可持续合作的同时激发研究人员发起的研究;并提出了 2 项行动:(a)召集一个工作组,专门讨论如何加快向 IBD 儿童提供药物治疗,(b)资助一项多中心临床和转化研究,包括建立关键研究基础设施。10.1093/ibd/izy205_video1izy205.video15799266615001.